We conducted two double-blind , randomized , placebo-controlled , phase 3 trials involving patients with mild-to-moderate Alzheimer 's disease -- one involving 1121 carriers of the apolipoprotein E ( APOE ) 4 allele and the other involving 1331 noncarriers .